📰 Clinical Development News
Page 76 - Clinical Development News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Clinical Development. Real-time updates on events, politics, business and more.
October 17, 2023
AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
October 17, 2023
In our first podcast interview of 2023, BioPharma Reporter spoke with Dr Sarah Bateup, therapy lead at Clerkenwell Health, about the potential of psychedelic medicine and her work within the psychedelic therapy training space.
October 16, 2023
– Long-Term & Real-World HIV Research Offer Insights into How Treatment with Biktarvy® and Sunlenca® May Help Inform the Future of Coordinated, Person-Centered HIV Care – – Updates on...
October 16, 2023
NANTES, France, October 16, 2023--Regulatory News: OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) presented the first Phase 1/2 positive clinical results with high affinity anti-PD1 monoclonal antibody OSE-279 in advanced solid tumors at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held in Boston, MA (October 11 – 15, 2023 - Abstract number 35371, Poster C063).
October 16, 2023
– Real-World Evidence and New Clinical Analysis Support the Role of Trodelvy® in Metastatic Breast Cancers – – New Data Demonstrate Potential of Trodelvy in Small Cell Lung Cancer,...
October 16, 2023
AI start-up, Leucine, claims ‘not fit for purpose’ compliance protocol processes are hindering the ability to deliver life-saving drugs faster.
October 16, 2023
A free of charge service to help sponsors identify any ‘zombie trials’ has been launched by Phesi in a bid to save sponsors time and money.
October 16, 2023
Patients with severe Alzheimer's Disease (AD) showed no cognitive decline throughout a ten-month trial while being treated with Bryostatin-1.
October 14, 2023
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches –
October 14, 2023
– Novel selective and reversible FGFR2 inhibitor exhibits strong potency across key primary and resistance driver mutations with potential advantages over covalent approaches – - IND and...